Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery

Annals of Surgical Oncology

Volumn 17, Issue 1, 2010, Pages 31-39

  Bradley, Ciarán T ^a   Brasel, Karen J ^a   Miller, Jessica Jane ^a   Pappas, Sam G ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CANCER PATIENT; CANCER SURGERY; COMPUTER MODEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEEP VEIN THROMBOSIS; DRUG COST; HEALTH CARE SYSTEM; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL DISCHARGE; HOSPITALIZATION COST; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MEDICARE; PATIENT COMPLIANCE; REIMBURSEMENT; SURGICAL PATIENT; THROMBOSIS; THROMBOSIS PREVENTION; UNITED STATES; VENOUS THROMBOEMBOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; COST-BENEFIT ANALYSIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PATIENT COMPLIANCE; PROGNOSIS; SURVIVAL RATE; VENOUS THROMBOEMBOLISM;

EID: 74649085976     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0671-6     Document Type: Article

References (39)

1. NH Osborne TW Wakefiled PK Henke 2008 Venous thromboembolism in cancer patients undergoing major surgery Ann Surg Oncol 15 3567 3578 10.1245/s10434-008-0151-4 18841419
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:381S-453S.
3. A Khushal D Quinlan R Alikhan, et al. 2002 Thromboembolic disease in surgery for malignancy-rationale for prolonged thromboprophylaxis Semin Thromb Hemost 28 569 576 10.1055/s-2002-36701 12536350 (Pubitemid 36027000)
4. MS Rasmussen 2002 Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis Cancer Treat Rev 28 141 144 10.1016/S0305-7372(02)00043-9 1:CAS:528:DC%2BD38XosVSmsLo%3D 12234565
5. D Bergqvist G Agnelli AT Cohen for the ENOXACAN II Investigators, et al. 2002 Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer N Engl J Med 346 975 980 10.1056/NEJMoa012385 1:CAS:528:DC%2BD38XitlCit7g%3D 11919306 (Pubitemid 34983247)
6. MS Rasmussen LN Jorgensen P Wille-Jorgensen for the FAME investigators, et al. 2006 Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study J Thromb Haemost 4 2384 2390 10.1111/j.1538-7836. 2006.02153.x 1:CAS:528:DC%2BD28Xht1yjtbnJ 16881934 (Pubitemid 44575433)
7. I Lausen R Jensen LN Jorgense, et al. 1998 Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis Eur J Surg 164 657 663 10.1080/110241598750005534 1:STN:280:DyaK1czps12rtw%3D%3D 9728784 (Pubitemid 28368781)
8. G Agnelli G Bolis L Capussotti, et al. 2006 A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS Project Ann Surg 243 89 95 10.1097/01.sla.0000193959.44677.48 16371741 (Pubitemid 43054059)
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Venous thromboembolic disease, v.2.2008. http://www.nccn.org/ professionals/physician-gls/PDF/vte.pdf. Accessed 23 August 2009.
10. GH Layman AA Khorana A Falanga, et al. 2007 American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer J Clin Oncol 25 5490 5505 10.1200/JCO.2007.14. 1283 (Pubitemid 350232226)
11. MA Stratton FA Anderson HI Bussey 2000 Prevention of venous thromboembolism. Adherence to the 1995 American College of Chest Physicians Consensus Guidelines for Surgical Patients Arch Intern Med 160 334 340 10.1001/archinte.160.3.334 1:STN:280:DC%2BD3c7jt1aluw%3D%3D 10668835
12. AK Kakkar M Levine HM Piedo R Wolfe J Wong 2003 Venous thrombosis in cancer patients: insights from the FRONTLINE survey Oncologist 8 381 388 10.1634/theoncologist.8-4-381 12897335 (Pubitemid 36929723)
13. RA Wolff 2003 Are Patients with Cancer Receiving Adequate thromboprophylaxis? Results from FRONTLINE Cancer Treat Rev 29 7 9 10.1016/S0305-7372(03)80002-6 12887943 (Pubitemid 36758231)
14. DM Arnold SR Kahn I Shrier 2001 Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines Chest 120 1964 1971 10.1378/chest.120.6.1964 1:STN:280: DC%2BD3MnpsVyktQ%3D%3D 11742929 (Pubitemid 34053461)
15. A Amin S Stemkowski J Lin G Yang 2008 Appropriate thromboprophylaxis in hospitalized cancer patients Clin Adv Hematol Oncol 6 910 920 19209141
16. P Mismetti S Leporte JT Darmon, et al. 2001 Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery Br J Surg 88 913 930 10.1046/j.0007-1323.2001.01800.x 1:STN:280:DC%2BD3MzovVOlug%3D%3D 11442521 (Pubitemid 34015572)
17. D Manganelli M Paxxagli D Mazzantini, et al. 1998 Prolonged prophylaxis with unfractionated heparin is effective to reduce delayed deep vein thrombosis in total hip replacement Respiration 65 369 374 10.1159/000029297 1:CAS:528:DyaK1cXntF2lu7w%3D 9782219 (Pubitemid 28491272)
18. CL Bennett PR Yarnold AM Evens, et al. 2006 Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer JAMA 296 2558 2560 10.1001/jama.296.21.2558-c 1:CAS:528:DC%2BD28Xht12lsbnJ 17148721
19. Pulmonary Embolism Prevention, (PEP) Trial Collaborative Group 2000 Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial Lancet 355 1295 1302 10.1016/S0140-6736(00)02110-3
20. TE Warkentin JG Kelton 1996 A 14-year study of heparin-induce thrombocytopenia Am J Med 101 502 507 10.1016/S0002-9343(96)00258-6 1:STN:280:DyaK2s7gsVWjtQ%3D%3D 8948273 (Pubitemid 126335970)
21. TE Warkentin MN Levine J Hirsh, et al. 1995 Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 332 1330 1335 10.1056/NEJM199505183322003 1:STN:280:DyaK2M3jtFGmug%3D%3D 7715641
22. PC Comp TE Spiro RJ Friedman for the Enoxaparin Clinical Trial Group, et al. 2001 Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement J Bone Joint Surg Am 83 336 345 11263636
23. A Planes N Vochelle JY Darmon, et al. 1996 Risk of Deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo Lancet 348 224 228 10.1016/S0140-6736(96)01453-5 1:CAS:528:DyaK28XltFSrtr4%3D 8684199 (Pubitemid 26254196)
24. OE Dahl G Andreassen T Aspelin, et al. 1997 Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin®) Thromb Haemost 77 26 31 1:CAS:528:DyaK2sXhtFSktrY%3D 9031444
25. D Bergqvist G Benoni O Bjorgell, et al. 1996 Low-molecular-weight heparin (Enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement N Engl J Med 335 696 700 10.1056/NEJM199609053351002 1:CAS:528:DyaK28XlvVOns7s%3D 8703168 (Pubitemid 26287355)
26. MR Lassen LC Borris BS Anderson, et al. 1998 Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-the Danish Prolonged Prophylaxis (DaPP) study Thromb Res 89 281 287 10.1016/S0049-3848(98)00018-8 1:CAS:528:DyaK1cXkt1KksLs%3D 9669750 (Pubitemid 28318383)
27. RD Hull GF Pineo C Francis, et al. 2000 Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients Arch Intern Med 160 2208 2215 10.1001/archinte.160.14.2208 1:CAS:528:DC%2BD3cXlslalsb4%3D 10904465 (Pubitemid 30482729)
28. JA Heit CG Elliott AA Trowbridge for the Ardeparin Arthroplasty Study Group, et al. 2000 Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomised, double-blind, placebo-controlled trial Ann Intern Med 132 853 861 1:CAS:528:DC%2BD3cXkt1Cnt7s%3D 10836911
29. N Martel J Lee PS Wells 2005 Risk for Heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis Blood 106 2710 2715 10.1182/blood-2005-04-1546 1:CAS:528:DC%2BD2MXhtFantbjE 15985543 (Pubitemid 41510744)
30. L Osterberg T Blaschke 2005 Adherence to medication N Engl J Med 353 487 497 10.1056/NEJMra050100 1:CAS:528:DC%2BD2MXntVCisL0%3D 16079372 (Pubitemid 41127293)
31. AJ Claxton J Cramer C Pierce 2001 A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 1296 1310 10.1016/S0149-2918(01)80109-0 1:STN:280:DC%2BD3MrhtVKktA%3D%3D 11558866 (Pubitemid 32804122)
32. Red Book. Montvale, NJ: Thompson, 2006.
33. Centers for Medicare and Medicaid Services. Medicare provider analysis and review database. http://www.cms.hhs.gov/MedicareFeeforSvcPartsAB/03-MEDPAR. asp. Accessed 23 August 2009.
34. Muennig P, Khan K. Designing and conducting cost-effectiveness analyses in medicine and health care. San Francisco: Jossey-Bass, 2002.
35. Centers for Medicare and Medicaid Services. Medicare hospital outpatient prospective payment system. http://www.cms.hhs.gov/HospitalOutpatientPPS/HORD/ itemdetail.asp?filterType=none&filterByDID=9&sortByDID=3&sortOrder= descending&itemID=CMS1185569. Accessed 23 August 2009.
36. National Cancer Databank. Patterns of diagnosis and treatment for selected cancers, 2006. http://cromwell.facs.org/BMarks/BMPub/Ver10/DxRx/BMPub- DxRx.cfm. Accessed 23 August 2009.
37. FP Sarasin H Bounameaux 1996 Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery Arch Surg 131 694 698 1:STN:280:DyaK283ptVCkuw%3D%3D 8678765
38. MMC Hovens JD Snoep JT Tamsma MV Huisman 2006 Aspirin in the prevention and treatment of venous thromboembolism J Thromb Haemost 4 1470 1475 10.1111/j.1538-7836.2006.01928.x 1:CAS:528:DC%2BD28XotVelu7k%3D 16839339 (Pubitemid 43919169)
39. WH Geerts GF Pineo JA Heit, et al. 2004 Prevention of venous thromboembolism. the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 338S 400S 10.1378/chest.126.3-suppl.338S 1:CAS:528: DC%2BD2cXptV2msbw%3D 15383478 (Pubitemid 39302602)